Survodutide Dosage Guide
50/100 confidenceComplete guide to Survodutide dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Dosage Overview
Dose Range
2.4 mg - 6 mg
Route
subcutaneous
Frequency
Weekly
Detailed Dosage Information
Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing.
Administration Method
Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027.
Research Backing
Phase 2 MASH trial: up to 87% MASH resolution at 48 weeks (6 mg). Phase 2b obesity trial: up to 18.7% weight loss at 46 weeks. Phase 3 SYNCHRONIZE (MASH) and ACHIEVE (obesity) programs ongoing.
Side Effects to Monitor
Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists.
Safety Considerations & Risks
Pre-approval medication — full safety profile not yet established. Glucagon receptor activation may transiently increase hepatic glucose output (theoretical concern for diabetic patients). Thyroid C-cell tumor risk not yet fully assessed. No long-term safety data beyond 48 weeks.